MedTrace Logo

Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer

NCT03495544 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 390

Last updated 2018-04-12

No results posted yet for this study

Summary

This is a multicentre, non-interventional, prospective study to be carried out in representative oncology departments / institutions in order to determine the association between the presence of germline DNA-repair genes mutations and PD-L1 expression level in tumour and immune cells in breast cancer. No additional procedures besides those already used in the routine clinical practice will be applied to the patients.

Conditions

  • Hereditary Breast Cancer

Interventions

DIAGNOSTIC_TEST

PD-L1 expression

IHC testing of PD-L1 expression level in tumor tissue samples

Sponsors & Collaborators

  • Tatarstan Cancer Center

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2019-03-17
Completion
2019-07-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03495544 on ClinicalTrials.gov